JP2014530231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530231A5 JP2014530231A5 JP2014535166A JP2014535166A JP2014530231A5 JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5 JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- container
- mdi
- metered dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201117621A GB201117621D0 (en) | 2011-10-12 | 2011-10-12 | Compositions |
| GB1117621.1 | 2011-10-12 | ||
| PCT/GB2012/052542 WO2013054135A1 (en) | 2011-10-12 | 2012-10-12 | Compositions comprising salbutamol sulphate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530231A JP2014530231A (ja) | 2014-11-17 |
| JP2014530231A5 true JP2014530231A5 (enExample) | 2014-12-25 |
| JP5818290B2 JP5818290B2 (ja) | 2015-11-18 |
Family
ID=45091933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535166A Active JP5818290B2 (ja) | 2011-10-12 | 2012-10-12 | 硫酸サルブタモールを含有する組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9114164B2 (enExample) |
| EP (1) | EP2766005B1 (enExample) |
| JP (1) | JP5818290B2 (enExample) |
| CN (1) | CN103857388B (enExample) |
| AU (1) | AU2012322453B2 (enExample) |
| BR (1) | BR112014008609B1 (enExample) |
| CA (1) | CA2851764C (enExample) |
| ES (1) | ES2556585T3 (enExample) |
| GB (1) | GB201117621D0 (enExample) |
| MX (1) | MX336225B (enExample) |
| WO (1) | WO2013054135A1 (enExample) |
| ZA (1) | ZA201402234B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| ES2761776T3 (es) | 2014-12-22 | 2020-05-21 | Suda Pharmaceuticals Ltd | Prevención y tratamiento de la enfermedad metastásica en pacientes con cáncer trombocitótico |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3701940B1 (en) * | 2015-12-04 | 2025-11-12 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| EP3515439B1 (en) * | 2016-09-19 | 2021-12-15 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| EP3515425B1 (en) * | 2016-09-19 | 2021-06-09 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising salmeterol |
| CN114515284A (zh) * | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
| US11260052B2 (en) * | 2016-09-19 | 2022-03-01 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| FR3130554B1 (fr) | 2021-12-20 | 2024-10-18 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| FR3137830A1 (fr) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| US7105152B1 (en) * | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| DK0617610T3 (da) | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
| WO1996019198A1 (en) | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol drug formulations |
| BR9604978A (pt) | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Inalador com dose medida |
| DE69813853T3 (de) * | 1997-09-29 | 2011-05-12 | Novartis Ag | Perforierte mikroteilchen und deren verwendung |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| GB2392164B (en) | 1999-09-11 | 2004-04-07 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| US20060018840A1 (en) | 2004-06-28 | 2006-01-26 | Nektar Therapeutics | Aerosolizable formulation comprising nicotine |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
-
2011
- 2011-10-12 GB GB201117621A patent/GB201117621D0/en not_active Ceased
-
2012
- 2012-10-12 JP JP2014535166A patent/JP5818290B2/ja active Active
- 2012-10-12 WO PCT/GB2012/052542 patent/WO2013054135A1/en not_active Ceased
- 2012-10-12 CN CN201280049813.9A patent/CN103857388B/zh active Active
- 2012-10-12 BR BR112014008609-5A patent/BR112014008609B1/pt active IP Right Grant
- 2012-10-12 MX MX2014004364A patent/MX336225B/es unknown
- 2012-10-12 EP EP12787053.3A patent/EP2766005B1/en active Active
- 2012-10-12 AU AU2012322453A patent/AU2012322453B2/en active Active
- 2012-10-12 CA CA2851764A patent/CA2851764C/en active Active
- 2012-10-12 ES ES12787053.3T patent/ES2556585T3/es active Active
- 2012-10-12 US US14/351,001 patent/US9114164B2/en active Active
-
2014
- 2014-03-26 ZA ZA2014/02234A patent/ZA201402234B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528470A5 (enExample) | ||
| JP2007106777A5 (enExample) | ||
| Zhou et al. | Emerging inhalation aerosol devices and strategies: where are we headed? | |
| JP2010132695A5 (enExample) | ||
| JP2009503104A5 (enExample) | ||
| HRP20140582T4 (hr) | Kombinacijska terapija za copd | |
| JP2009269923A5 (enExample) | ||
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| JP2013544781A5 (enExample) | ||
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
| PH12014502746A1 (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| EP4233874A3 (en) | Acetylsalicylic acid for reducing the risk of a thromboembolic event | |
| MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
| NZ599900A (en) | Pharmaceutical suspension aerosol formulations for use in metered dose inhalers | |
| CY1117596T1 (el) | Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης | |
| WO2011061498A3 (en) | Inhalation solutions | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| MX2014001940A (es) | Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal. | |
| JP2015533131A5 (enExample) | ||
| WO2011049540A3 (en) | The pharmaceutical composition in dry powder form for inhalation |